---
title: "Orchid Pharma Ltd (ORCHPHARMA) — Share Price, Financials & Analysis"
symbol: "ORCHPHARMA"
company: "Orchid Pharma Ltd"
canonical: "https://tapetide.com/stocks/ORCHPHARMA"
isin: "INE191A01027"
nse_symbol: "ORCHPHARMA"
bse_code: "524372"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 4967.43
generated_at: "2026-09-13T18:52:16.765Z"
---

# Orchid Pharma Ltd (ORCHPHARMA)

Canonical page: https://tapetide.com/stocks/ORCHPHARMA

## Company

- **NSE Symbol:** ORCHPHARMA
- **BSE Code:** 524372
- **ISIN:** INE191A01027
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2020-11-02
- **CEO:** Mr. Manish Dhanuka
- **Employees:** 736
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** orchidpharma.com

## About

Orchid Pharma is a pharmaceutical company engaged in the development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. [1]

## Latest Price

- **Price:** ₹1003.05
- **Change:** -13.05 (-1.28%)
- **Open:** ₹1005.5
- **Day High:** ₹1010
- **Day Low:** ₹973.55
- **Previous Close:** ₹1016.1
- **Volume:** 68916
- **As Of:** 2026-09-11T10:20:41+00:00

## Key Fundamentals

Observed at 2026-09-11T04:35:56.124198Z.

- **Market Cap:** ₹4967.43 Cr
- **Classification:** Microcap
- **P/E (reported):** 567.2
- **P/E (TTM):** 477.64
- **EPS (TTM):** ₹2.1
- **EPS (reported):** ₹21.99
- **Book Value:** ₹216.57
- **Price to Book:** 4.69
- **Dividend Yield:** 0%
- **ROE:** 7.56%
- **ROCE:** 7.85%
- **Debt to Equity:** 0.28
- **Revenue (yearly):** ₹811.33 Cr
- **Net Income:** ₹21.02 Cr
- **EBITDA:** ₹34.02 Cr
- **52-Week High:** ₹1133
- **52-Week Low:** ₹480
- **RSI (14):** 55.39

## Tapetide Score

- **Score:** 38 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Rising
- **Percentile:** 10.2 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 43.66 | 9% |
| growth | 50 | 9% |
| momentum | 80.44 | 12% |
| ownership | 60.14 | 24% |
| quality | 33.95 | 22% |
| valuation | 14.27 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Weaknesses

- Stock is trading at 3.95 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Tax rate seems low
- Company has a low return on equity of 6.12% over last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.18.6 Cr.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -84.74% | 4.8% | -18.52% |
| ebitda margin growth | -58.09% | -73.62% | -75.86% | -63.22% |
| net income growth | -87.6% | -78.06% | 40% | 17% |
| revenue growth | -18.64% | -14.54% | 23% | 22% |
| roce | -81.8% | -6.21% | -23.41% | 3.92% |
| roe | -87.5% | -7.01% | 7.9% | -151.82% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 198.76 | 220.59 | 217.1 | 244.41 | 222.7 | 217.34 | 237.48 | 263.19 | 193.52 | 207.27 | 368.33 | 304.17 |
| Expenses | 175.46 | 185.21 | 188.19 | 211.92 | 192.36 | 190.97 | 209.49 | 268.84 | 194.99 | 205.71 | 338.17 | 290.17 |
| Operating Profit | 23.3 | 35.38 | 28.91 | 32.49 | 30.34 | 26.37 | 27.99 | -5.65 | -1.47 | 1.56 | 30.16 | 14 |
| OPM % | 11.72 | 16.04 | 13.32 | 13.29 | 13.62 | 12.13 | 11.79 | -2.15 | -0.76 | 0.75 | 8.19 | 4.6 |
| Other Income | 8.36 | 7.62 | 13.36 | 7.57 | 7.52 | 8.49 | 3.9 | 11.57 | 10.77 | -1.5 | 7.55 | 1.83 |
| Interest | 3.8 | 3.54 | 3.47 | 3.5 | 3.33 | 3.8 | 3.92 | 2.28 | 3.73 | 3.18 | 1.96 | 2.23 |
| Depreciation | 7.84 | 9.27 | 8.42 | 8.44 | 8.63 | 8.61 | 8.87 | 10.53 | 8.9 | 9.03 | 10.9 | 10.95 |
| Profit before tax | 20.02 | 30.19 | 30.38 | 28.12 | 25.9 | 22.45 | 19.1 | -6.89 | -3.33 | -12.15 | 24.85 | 2.65 |
| Tax % | 0 | 0 | -10.27 | -0.53 | 0 | 0 | -0.21 | 0 | 0 | 0 | 0 | 2.64 |
| Net Profit | 19.8 | 29.43 | 32.96 | 29.35 | 27.24 | 20.78 | 22.29 | -5.69 | -5.72 | -12.61 | 25.84 | 3.22 |
| EPS in Rs | 3.9 | 5.8 | 6.5 | 5.79 | 5.37 | 4.1 | 4.39 | -1.12 | -1.13 | -2.49 | 5.09 | 0.63 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 683 | 600 | 484 | 450 | 560 | 666 | 819 | 922 | 1233 | 1073 |
| Expenses | 659 | 612 | 515 | 421 | 505 | 581 | 708 | 804 | 1199 | 1029 |
| Operating Profit | 24 | -12 | -31 | 29 | 55 | 84 | 111 | 118 | 34 | 44 |
| OPM % | 3.6 | -2 | -6 | 7 | 10 | 13 | 14 | 13 | 2.7 | 4.1 |
| Other Income | 20 | 218 | 24 | 15 | 67 | 52 | 31 | 27 | 29 | 19 |
| Interest | 310 | 7 | 6 | 52 | 33 | 33 | 17 | 15 | 9 | 11 |
| Depreciation | 133 | 130 | 118 | 109 | 87 | 55 | 33 | 35 | 43 | 40 |
| Profit before tax | -399 | 69 | -131 | -117 | 2 | 48 | 92 | 96 | 10 | 12 |
| Tax % | -12 | 0 | 0 | 0 | 0 | 0 | -3 | 0 | -2 | — |
| Net Profit | -353 | 69 | -131 | -117 | -2 | 46 | 92 | 100 | 10 | 11 |
| EPS in Rs | -39.65 | 7.8 | -32.11 | -28.55 | -0.48 | 11.35 | 18.17 | 19.65 | 1.96 | 2.1 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 89 | 89 | 89 | 41 | 41 | 41 | 41 | 51 | 51 | 51 |
| Reserves | -556 | -881 | -793 | 725 | 612 | 607 | 648 | 1119 | 1217 | 1237 |
| Borrowings | 3106 | 3202 | 3230 | 566 | 453 | 268 | 331 | 135 | 175 | 363 |
| Other Liabilities | 616 | 715 | 551 | 128 | 132 | 195 | 205 | 249 | 246 | 261 |
| Total Liabilities | 3256 | 3125 | 3077 | 1460 | 1237 | 1111 | 1225 | 1554 | 1688 | 1911 |
| Fixed Assets | 1497 | 1386 | 1256 | 858 | 670 | 584 | 573 | 620 | 633 | 692 |
| CWIP | 288 | 272 | 278 | 26 | 7 | 10 | 46 | 31 | 81 | 341 |
| Investments | 1 | 1 | 0 | 0 | 15 | 45 | 44 | 46 | 50 | 53 |
| Other Assets | 1470 | 1467 | 1542 | 576 | 544 | 472 | 561 | 857 | 925 | 826 |
| Total Assets | 3256 | 3125 | 3077 | 1460 | 1237 | 1111 | 1225 | 1554 | 1688 | 1911 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 401 | 9 | 12 | 81 | 24 | 92 | 18 | 126 | 19 | 101 |
| Cash from Investing Activity | -176 | -28 | 45 | 167 | 67 | 113 | -31 | -312 | -27 | -285 |
| Cash from Financing Activity | -465 | 33 | 0 | -250 | -165 | -217 | 31 | 167 | 25 | 170 |
| Net Cash Flow | -240 | 15 | 57 | -2 | -74 | -11 | 18 | -19 | 18 | -14 |
| Free Cash Flow | 392 | 3 | 5 | 77 | 23 | 238 | -8 | 61 | -131 | -273 |
| CFO/OP | 13628 | 67 | -138 | -226 | 63 | 173 | 22 | 113 | 17 | 293 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 75 | 64 | 73 | 51 | 110 | 111 | 118 | 87 | 96 | 78 |
| Inventory Days | 196 | 202 | 214 | 254 | 244 | 201 | 217 | 199 | 219 | 111 |
| Days Payable | 402 | 374 | 381 | 182 | 176 | 195 | 165 | 173 | 149 | 99 |
| Cash Conversion Cycle | -130 | -108 | -94 | 123 | 179 | 117 | 170 | 113 | 166 | 90 |
| Working Capital Days | -500 | -876 | -1158 | 166 | 302 | 97 | 54 | 118 | 135 | 95 |
| ROCE % | -4 | -4 | -5 | -6 | -5 | -2 | 5 | 9 | 8 | 2 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 72.4% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% |
| FIIs | 8.08% | 4.14% | 1.96% | 1.42% | 1.94% | 2.53% | 2.69% | 1.4% | 1.56% | 1.17% | 0.87% | 0.81% |
| DIIs | 9.88% | 14.5% | 17.73% | 18.93% | 18.29% | 18.99% | 20.1% | 19.43% | 19.04% | 19.39% | 20.25% | 20.75% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 3.85% | 7.79% | 7.44% | 7.16% | 7.59% | 6.42% | 5.11% | 6.91% | 7.03% | 6.76% | 6.58% | 6.21% |
| Others | 5.79% | 3.74% | 3.03% | 2.65% | 2.35% | 2.22% | 2.27% | 2.43% | 2.54% | 2.84% | 2.47% | 2.4% |
| No. of Shareholders | 29197 | 36931 | 36720 | 34695 | 36363 | 34158 | 34303 | 39827 | 38155 | 35709 | 35118 | 33433 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 12 / 7 / 0

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 970.31 | Buy |
| EMA (10) | 984.83 | Buy |
| SMA (20) | 979.33 | Buy |
| EMA (20) | 985.12 | Buy |
| SMA (50) | 1001.26 | Buy |
| EMA (50) | 971.44 | Buy |
| SMA (100) | 897.96 | Buy |
| EMA (100) | 910.95 | Buy |
| SMA (200) | 788.42 | Buy |
| EMA (200) | 846.1 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 53.01 | Neutral |
| MACD (12,26,9) | -2.15 | Buy |
| Stochastic (14,3,3) | 65.77 | Neutral |
| ADX (14) | 14.99 | Neutral |
| Williams %R (14) | -42.62 | Neutral |
| ATR (14) | 43.86 | High Volatility |
| ROC (12) | 3.05 | Buy |
| Stoch RSI (14) | 78.04 | Neutral |
| UO (7,14,28) | 59.03 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 0 | 0% |
| Hold | 1 | 100% |
| Sell | 0 | 0% |

Based on 1 analyst ratings, observed at 2026-09-11T04:35:53.182967+00:00.

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-08 | [Business Responsibility and Sustainability Reporting (BRSR)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2c20eebb-ab3c-4494-afc0-c74880ca212f.pdf) |
| 2026-09-08 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9173803d-c576-421f-8c50-d8a9d14f5590.pdf) |
| 2026-09-07 | [Notice Of 33Rd Annual General Meeting Of Orchid Pharma Limited (The Company) For The F.Y. 2025-26](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3a7d7e02-eefd-4e32-9cb4-28c1e60c3205.pdf) |
| 2026-09-03 | [Board Meeting Outcome for Outcome Of Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ab22406e-01fa-41bf-8e1a-585beee8ebf6.pdf) |
| 2026-09-03 | [Announcement under Regulation 30 (LODR)-Change in Management](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d59a196c-650e-4195-9fee-054b8eeb0503.pdf) |
| 2026-08-17 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7f07d618-a643-4d19-a21d-da25bb5be57f.pdf) |
| 2026-08-14 | [Board Meeting Outcome for Outcome Of Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4290d7f9-5fd3-407b-9ca2-cf3848be6cd9.pdf) |
| 2026-08-14 | [Outcome Of Board Meeting Held For Considering And Approving Revised Audited Financial Results For The Year Ended March 31 2026 Pursuant To Scheme Of Merger.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c592cea8-74ab-4674-abb7-8649eeefeaac.pdf) |
| 2026-08-14 | [Announcement under Regulation 30 (LODR)-Monitoring Agency Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=09b76d67-19f6-48ca-b185-7e8478e7b0f1.pdf) |
| 2026-08-14 | [Statement Of Deviation Or Variation For The Quarter Ended June 30 2026 On The Use Of Proceeds Of Funds Raised Through Qualified Institutional Placement](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eef1570e-127a-4e0d-9cd1-a327667695f0.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-24 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6a5dbb9c-1105-489f-8c8c-35ebf2e46ed5.pdf) |
| 2026-06-01 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=19c11f22-58cb-47df-afdc-5f14d4c949cf.pdf) |
| 2026-02-16 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=948a97e7-60cd-4337-87c6-2b6a143d5afa.pdf) |
| 2025-11-17 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4424c13c-8f23-49e1-b630-4d5464d9f240.pdf) |
| 2025-08-14 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fae146e7-56e5-4373-9698-6e93c752fd5c.pdf) |
| 2025-06-02 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dcf5f67e-4d5b-4737-90a6-03c6644f124a.pdf) |
| 2025-02-15 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7ba7c57c-42b0-4766-9e96-76f618bc6b91.pdf) |
| 2024-11-15 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dd7ca577-5c5b-4336-b529-f3dc78144921.pdf) |
| 2024-08-17 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=99977bd2-71eb-493d-a563-5b112ac1b2f0.pdf) |
| 2024-05-29 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b22861ec-3c50-416e-897d-97aa40d2498d.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-08-21 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e658c898-7d11-4cdd-a385-48fa0c390f3f.pdf) |
| 2026-02-12 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7fdc72b0-91a1-4189-bbc2-24c2d64cec2a.pdf) |
| 2025-11-11 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eb8416c4-c432-4e44-bf69-63627f93f764.pdf) |
| 2025-08-12 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5974295d-425e-4088-a9e9-7c76f1902162.pdf) |
| 2025-05-26 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=48115633-c9d9-45f6-83e3-e1c4500f3cd6.pdf) |
| 2024-11-11 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cbb6e04e-8096-481c-9de5-b591e1bae79a.pdf) |
| 2024-08-13 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1fcf20b9-942d-4494-a040-32d997bd8e2c.pdf) |
| 2024-05-24 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=83cf7263-544d-40b0-bbea-655e9b257477.pdf) |
| 2023-11-06 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5a0ecca0-1137-4e4e-b291-17c158d206d2.pdf) |
| 2023-08-14 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0b3ca8ea-39fb-423a-b1b6-9c6efb8d3e1c.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-20 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1a6cbc40-b30a-4359-81d9-3dd1df920019.pdf) |
| 2026-05-26 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3022a5b4-4d8e-40e8-ae14-0e597d8634cb.pdf) |
| 2026-02-11 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9a21b328-f927-43c9-83cb-c1112f37bf04.pdf) |
| 2025-11-11 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d207b0b0-043d-4d16-b3d5-57a929c180cd.pdf) |
| 2025-08-12 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2e356cbc-55b6-49b8-8e6b-a336760bb3e6.pdf) |
| 2025-05-26 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4636c79d-2779-45fd-90b0-bbb702ff8caa.pdf) |
| 2025-02-12 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a747e4a9-cd5b-43b3-8f2e-40c079aaaf9f.pdf) |
| 2024-11-11 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=973e25de-97c7-444b-a731-5642d7e8bfc2.pdf) |
| 2024-08-13 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0ab4b5c0-26de-4869-ba25-fd58974cebed.pdf) |
| 2024-05-23 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fa33e2d1-2388-4fb0-9240-54ebf4b6ebaa.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-14 | [Financial Results For Quarter-1 Of F.Y. 2026-27 Ended June 30 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ea4652ff-1826-4c8e-8e46-3ab0a83fd9e5.pdf) |
| 2026-05-25 | [Board Meeting Outcome For Outcome Of Board Meeting For Considering And Approving Annual Audited Financial Results For The Quarter And F.Y. Ended On March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d98bb500-443b-41ec-b073-086a3bda65f3.pdf) |
| 2026-02-11 | [Quarterly Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7296e13a-19e7-4b8d-8f4f-d497f8f722a0.pdf) |
| 2025-11-11 | [Unaudited Limited Reviewed Financial Results For Q-2 Of F.Y.2025-26](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8e8feff4-1fe0-4fc1-9d32-faa9109a5f68.pdf) |
| 2025-08-12 | [Outcome Of Board Meeting Inter-Alia For Consideration And Approval Of Financial Results For The Q-1 Of F.Y.2025-26 Ended On June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ab6569cb-597c-4a53-9317-d573b934fdd2.pdf) |
| 2025-05-26 | [Annual Audited Financial Results For The Quarter And F.Y. Ended On March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=01febc5e-06ff-4950-b96a-bc83e42d038a.pdf) |
| 2025-02-12 | [Outcome Of The Board Meeting Held For Inter Alia Consideration And Approval Of Unaudited Limited Reviewed Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended On Decemb](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=43359b09-b28e-47da-96e3-a304163e4fff.pdf) |
| 2024-11-11 | [Unaudited Financial Results For The Quarter And Half Year Ended On September 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3d86b0ab-48fa-4fbc-b14a-f3ff9f954160.pdf) |
| 2024-08-12 | [Financial Results For The Qtr June 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=01292b1b-b156-42ba-9183-e2f424bd62ff.pdf) |
| 2024-05-23 | [Audited Financial Results For Financial Year Ended On March 31, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=31a6c667-0f71-41f3-ab03-0fe76460765b.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4424c13c-8f23-49e1-b630-4d5464d9f240.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/dd7ca577-5c5b-4336-b529-f3dc78144921.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0cb5f432-19fc-476b-a7d3-1a385bf9b15c.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/57960835-3b34-44c1-bffc-ff6eb71f405f.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d99be6c5-2bc6-4ae1-8c28-d8fc16c3da1a.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d99be6c5-2bc6-4ae1-8c28-d8fc16c3da1a.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/244a778e-64dd-40d5-8e88-5e6ee60486f5.pdf) |
| Nov 2021 | [Concall - Nov 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d2b4e36f-9685-450b-b9a0-8012f306da98.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3022a5b4-4d8e-40e8-ae14-0e597d8634cb.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/3022a5b4-4d8e-40e8-ae14-0e597d8634cb.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Apr - Confirmation certificate under Regulation 74(5) of SEBI (Depositories and participants) Regulations, 2018 for the Quarter- IV ended on March 31, 2026 of FY 2025-26. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Apr - Confirmation certificate under Regulation 74(5) of SEBI (Depositories and participants) Regulations, 2018 for the Quarter- IV ended on March 31, 2026 of FY 2025-26.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/61bb7d19-b2b3-4308-a134-e4de15bfbabc.pdf) |
| 7 Apr - Orchid Pharma to join a physical investor roadshow on April 10, 2026 in Gurugram. | [Investor Roadshow Scheduled To Be Held On April 10, 2026. 7 Apr - Orchid Pharma to join a physical investor roadshow on April 10, 2026 in Gurugram.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/92371179-77fa-45b5-9943-2e1527049f37.pdf) |
| 27 Mar - Trading window closed from April 1, 2026 until 48 hours after audited results for FY ending March 31, 2026. | [Closure of Trading Window 27 Mar - Trading window closed from April 1, 2026 until 48 hours after audited results for FY ending March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/857b69b4-de76-41b9-9097-db63404c210d.pdf) |
| 2 Apr - CARE downgraded Orchid Pharma’s ₹207.5 crore long-term rating to BBB+; stable, and reaffirmed ₹84 crore short-term A2. | [Announcement under Regulation 30 (LODR)-Credit Rating 2 Apr - CARE downgraded Orchid Pharma’s ₹207.5 crore long-term rating to BBB+; stable, and reaffirmed ₹84 crore short-term A2.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d359543e-7bc8-46d1-a3cc-208ea823e7cf.pdf) |
| 18 Mar - NCLT reserved order on March 18, 2026 for Dhanuka Laboratories' amalgamation with Orchid Pharma. | [Update Related To The Scheme Of Amalgamation Of Dhanuka Laboratories Limited (''Amalgamating Company'') With Orchid Pharma Limited (''Amalgamated Company'') And Their Respective Shareholders And Creditors (''The Scheme'') Under Regulation 30 Of SEBI (LODR) Regulations, 2015 18 Mar - NCLT reserved order on March 18, 2026 for Dhanuka Laboratories' amalgamation with Orchid Pharma.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/43b902cc-b58f-429d-b9b7-94ad2955dfee.pdf) |
| 16 Feb - Q3 sales INR207 crore, 9M INR574 crore; EBITDA compressed; 7ACA mechanical completion Sep 2026; Exblifep launched in Spain, Italy. | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript 16 Feb - Q3 sales INR207 crore, 9M INR574 crore; EBITDA compressed; 7ACA mechanical completion Sep 2026; Exblifep launched in Spain, Italy.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/948a97e7-60cd-4337-87c6-2b6a143d5afa.pdf) |
| 12 Feb - Audio recording of Feb 12, 2026 analysts/investors earnings call for Q3 ended Dec 31, 2025; link provided. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 12 Feb - Audio recording of Feb 12, 2026 analysts/investors earnings call for Q3 ended Dec 31, 2025; link provided.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7fdc72b0-91a1-4189-bbc2-24c2d64cec2a.pdf) |
| 11 Feb - Investor Presentation Quarter III ended on December 31, 2025. | [Announcement under Regulation 30 (LODR)-Investor Presentation 11 Feb - Investor Presentation Quarter III ended on December 31, 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9a21b328-f927-43c9-83cb-c1112f37bf04.pdf) |
| 11 Feb - CARE report on Rs.400 crore QIP for quarter ended Dec 31, 2025; no deviations; Jammu land delays noted. | [Announcement under Regulation 30 (LODR)-Monitoring Agency Report 11 Feb - CARE report on Rs.400 crore QIP for quarter ended Dec 31, 2025; no deviations; Jammu land delays noted.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/19088348-19c7-42c4-9d79-b030d4bf5b16.pdf) |
| 11 Feb - Board approved Q3/9 results to Dec 31, 2025; Rs.711.27 lakh labour exceptional charge; NCLT hearing March 2, 2026 | [Board Meeting Outcome for Unaudited Limited Review Standalone & Consolidated Financial Results For The Quarter And Year To Date Ended On December 31, 2025 11 Feb - Board approved Q3/9 results to Dec 31, 2025; Rs.711.27 lakh labour exceptional charge; NCLT hearing March 2, 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/07cb1609-fd61-4fae-8f84-c5af45a7efa5.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2013 from nse](https://archives.nseindia.com/annual_reports/AR_3253_ORCHIDCHEM_2012_2013_11042014092423.zip) |
| from nse | [Annual Report 2012 from nse](https://archives.nseindia.com/annual_reports/AR_ORCHIDCHEM_2011_2012_18092012111802.zip) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b0642cbc-43b9-4e32-80ed-e6f09a8c984b.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/aade6f08-f6e7-441d-906a-293afb7c005a.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9a1f85f5-d692-4d89-b28f-b1bad57ad330.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/524372/73268524372.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/524372/69078524372.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/524372/67908524372.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/524372/5243720319.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/524372/5243720318.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:52:16.765Z.